EUVIMEDEUVIMED entdecken
Open Access

CBX4 suppresses CD8 + T cell antitumor immunity by reprogramming glycolytic metabolism

Jingzeng Wang, Wenlong Jia, Xi Zhou, Zhibo Ma, Jing Liu, Peixiang Lan

Theranostics · 2024

DOI: 10.7150/thno.95748 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Theranostics, 2024. Verfasst von Jingzeng Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Key Laboratory of Organ T…. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Glycolysis, Tumor Microenvironment, Mice, Knockout. Die Arbeit wurde bisher 28-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

CD8+ T cells undergo a series of metabolic reprogramming processes during their activation and proliferation, including increased glycolysis, decreased aerobic oxidation of sugars, increased amino acid metabolism and increased protein synthesis. However, it is still unclear what factors regulate these metabolic reprogramming processes in CD8+ T cells in the tumor immune microenvironment.

Methods

T cell chromobox protein 4 (CBX4) knock-out mice models were used to determine the role of CBX4 in CD8+ T cells on the tumor immune microenvironment and tumor progression. Flow cytometry, Cut-Tag qPCR, Chip-seq, immunoprecipitation, metabolite detection, lentivirus infection and adoptive T cells transfer were performed to explore the underlying mechanisms of CBX4 knock-out in promoting CD8+ T cell activation and inhibiting tumor growth.

Results

We found that CBX4 expression was induced in tumor-infiltrating CD8+ T cells and inhibited CD8+ T cell function by regulating glucose metabolism in tumor tissue. Mechanistically, CBX4 increases the expression of the metabolism-associated molecule aldolase B (Aldob) through sumoylation of trans-acting transcription factor 1 (SP1) and Krüppel-like factor 3 (KLF3). In addition, Aldob inhibits glycolysis and ATP synthesis in T cells by reducing the phosphorylation of the serine/threonine protein kinase (Akt) and ultimately suppresses CD8+ T cell function. Significantly, knocking out CBX4 may improve the efficacy of anti-PD-1 therapy by enhancing the function of CD8+ T cells in the tumor microenvironment.

Conclusion

CBX4 is involved in CD8+ T cell metabolic reprogramming and functional persistence in tumor tissues, and serves as an inhibitor in CD8+ T cells' glycolysis and effector function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesGlycolysisTumor MicroenvironmentMice, KnockoutAnimalsMiceCell Line, TumorMice, Inbred C57BLFructose-Bisphosphate AldolasePolycomb-Group ProteinsKruppel-Like Transcription FactorsHumansCellular Reprogramming

Stichwörter der Autor:innen

AldobCBX4CD8+ T cellanti-tumorglucose metabolism

Substanzen

Fructose-Bisphosphate AldolasePolycomb-Group ProteinsKruppel-Like Transcription Factors

Autor:innen und Institutionen

  • Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Key Laboratory of Organ Transplantation, Ministry of Education, NHC Key Laboratory of Organ Tra…
  • Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Clinical Medical Research Center of Hepatic Surgery at Hubei Province, Wuhan, China.

Zitieren

APA

Wang, J., Jia, W., Zhou, X., Ma, Z., Liu, J., & Lan, P. (2024). CBX4 suppresses CD8 + T cell antitumor immunity by reprogramming glycolytic metabolism. Theranostics. https://doi.org/10.7150/thno.95748

Vancouver

Wang J, Jia W, Zhou X, Ma Z, Liu J, Lan P. CBX4 suppresses CD8 + T cell antitumor immunity by reprogramming glycolytic metabolism. Theranostics. 2024. doi:10.7150/thno.95748

BibTeX
@article{Wang2024,
  author = {Wang, Jingzeng and Jia, Wenlong and Zhou, Xi and Ma, Zhibo and Liu, Jing and Lan, Peixiang},
  title = {CBX4 suppresses CD8 + T cell antitumor immunity by reprogramming glycolytic metabolism},
  journal = {Theranostics},
  year = {2024},
  doi = {10.7150/thno.95748}
}
Kostenlos starten →